Tejnaksh Health.

Why is Tejnaksh Healthcare Ltd falling/rising?

As of 01-Sep, Tejnaksh Healthcare Ltd's stock price is at 13.53, down 1.38%, reflecting significant long-term underperformance with a 26.43% drop over the past year and a 60.40% decline over three years. Weak fundamentals, low profitability, and decreased investor participation contribute to the stock's ongoing challenges.

As of 01-Sep, Tejnaksh Healthcare Ltd's stock price is falling, currently at 13.53, reflecting a decrease of 0.19 or 1.38%. This decline is part of a broader trend, as the stock has underperformed significantly over various time frames, including a 26.43% drop over the past year and a staggering 60.40% decline over the last three years. <BR><BR>The stock's performance today shows it has outperformed its sector by 0.59%, but this is overshadowed by a substantial decrease in investor participation, with delivery volume falling by 51.02% compared to the five-day average. Additionally, while the stock is trading at a fair value relative to its peers, its profitability is concerning, with a return on equity (ROE) of only 4.5% and a significant profit decline of 37.7% over the past year. <BR><BR>The long-term fundamentals appear weak, with a compound annual growth rate (CAGR) of operating profits at -17.81% over the last five years. This consistent underperformance against benchmarks, including a 9.74% decline year-to-date, contributes to the stock's falling price. Overall, these factors indicate a challenging environment for Tejnaksh Healthcare Ltd, leading to its current price decline.

Who are in the management team of Tejnaksh Health.?

The management team of Tejnaksh Health includes Ashish Vishwas Rawandale (Chairman/Executive Director), Preeti Ashish Rawandale (Non-Executive Director), Kiran Madhavrao Pawar, Vikramsinh Satish Khatal Patil, and Suhas Vasantrao Thorat (all Independent Non-Executive Directors), and Sanjay Bhikajirao Khatak (Non-Executive Director).

The management team of Tejnaksh Health includes the following individuals:<BR><BR>1. **Ashish Vishwas Rawandale** - Chairman / Executive Director<BR>2. **Preeti Ashish Rawandale** - Non-Executive & Non-Independent Director<BR>3. **Kiran Madhavrao Pawar** - Independent Non-Executive Director<BR>4. **Vikramsinh Satish Khatal Patil** - Independent Non-Executive Director<BR>5. **Sanjay Bhikajirao Khatak** - Non-Executive & Non-Independent Director<BR>6. **Suhas Vasantrao Thorat** - Independent Non-Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Tejnaksh Health. do?

Tejnaksh Healthcare Ltd is a micro-cap company based in Mumbai, providing urology services through its ISO certified hospital. As of June 2026, it reported net sales of 3 Cr and a market cap of INR 29 Cr.

Overview: <BR>Tejnaksh Healthcare Ltd operates in the healthcare services industry as a micro-cap company, providing a comprehensive range of urology services through its ISO certified hospital.<BR><BR>History: <BR>Tejnaksh Healthcare Ltd was incorporated in 2008 in Mumbai and transitioned from a Private Limited Company to a Public Limited Company on 10 March 2015. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 3 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 29 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.07 <BR>Return on Equity: 4.49% <BR>Price to Book: 1.04 <BR><BR>Contact Details: <BR>Address: A 601 Floor No 6 Kailash, Business Park Veer SavarkarMar Mumbai Maharashtra : 400079 <BR>Email: cs.tejnaksh@gmail.com <BR>Website: http://www.tejnaksh.com

Who are the peers of the Tejnaksh Health.?

Tejnaksh Health's peers include Centenial Surgic, GKB Ophthalmics, Deccan Healthcar, Bandaram Pharma, and others. GKB Ophthalmics shows the highest 1-year return, while Tejnaksh Health has a return of -25.80%.

Peers: The peers of Tejnaksh Health are Centenial Surgic, GKB Ophthalmics, Deccan Healthcar, Bandaram Pharma, Chennai Meena, Adeshwar Meditex, Samsrita Labs, Transgene Biotek, Sunrest Lifescie, and Galaxy Medicare.<BR><BR>Quality Snapshot: Below Average management risk is observed at Centenial Surgic, GKB Ophthalmics, Deccan Healthcar, Bandaram Pharma, Tejnaksh Health, Adeshwar Meditex, and the rest. Good growth is noted at GKB Ophthalmics, Deccan Healthcar, and the rest, while Excellent growth is found at Bandaram Pharma. Tejnaksh Health has a Good capital structure, alongside GKB Ophthalmics and Deccan Healthcar, while Average capital structure is seen at Centenial Surgic and Adeshwar Meditex.<BR><BR>Return Snapshot: The peer with the highest 1-year return is GKB Ophthalmics with N/A, while Deccan Healthcar has the lowest at -33.81%, and Tejnaksh Health's own 1-year return is -25.80%. Additionally, the peers with negative six-month returns include Deccan Healthcar, Bandaram Pharma, Samsrita Labs, and Transgene Biotek.

How big is Tejnaksh Health.?

As of 31st August, Tejnaksh Healthcare Ltd has a market capitalization of 29.00 Cr, with recent net sales of 10.80 Cr and a net profit of 1.24 Cr. Shareholder's funds are 25.91 Cr, and total assets are valued at 30.31 Cr.

As of 31st August, Tejnaksh Healthcare Ltd has a market capitalization of 29.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Tejnaksh Healthcare Ltd reported Net Sales of 10.80 Cr and a Net Profit of 1.24 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 25.91 Cr and Total Assets valued at 30.31 Cr.

Which are the latest news on Tejnaksh Health.?

Should I buy, sell or hold Tejnaksh Healthcare Ltd?

Are Tejnaksh Healthcare Ltd latest results good or bad?

Tejnaksh Healthcare Ltd's latest results show improved operating margins and a sequential profit recovery, but a 20.56% year-on-year decline in net sales raises concerns about its long-term viability. Investors should be cautious due to these ongoing revenue challenges.

Tejnaksh Healthcare Ltd's latest results present a mixed picture. On one hand, the company has shown some improvement in operating margins, which increased to 27.84% from 21.81% year-on-year. This suggests that the company has been able to manage its costs more effectively. Additionally, the consolidated net profit rose by 20% quarter-on-quarter to ₹0.36 crores, indicating a recovery in profitability on a sequential basis.<BR><BR>However, the overall performance is overshadowed by significant challenges. Net sales contracted by 20.56% year-on-year to ₹2.55 crores, marking the third consecutive quarter of year-on-year revenue decline. This persistent drop raises concerns about the company's ability to attract and retain patients, particularly in a competitive healthcare environment. The stock has also reacted negatively to these results, trading down 0.65% and sitting significantly below its 52-week high.<BR><BR>In summary, while there are signs of improved cost management and sequential profit recovery, the ongoing decline in revenue is a serious concern, indicating that the company is facing structural challenges that could impact its long-term viability. Investors should be cautious and monitor future performance closely.

When is the next results date for Tejnaksh Healthcare Ltd?

The next results date for Tejnaksh Healthcare Ltd is 30 May 2026.

The next results date for Tejnaksh Healthcare Ltd is scheduled for 30 May 2026.

How has been the historical performance of Tejnaksh Health.?

Tejnaksh Health's historical performance shows fluctuating net sales and profits, with a decline from Mar'19 to Mar'20, followed by recovery; net sales rose to 12.90 Cr in Mar'25 from 11.73 Cr in Mar'23, but cash flow from operations dropped to 0.00 Cr in Mar'25, indicating challenges despite improved profits.

Answer:<BR>The historical performance of Tejnaksh Health shows a fluctuating trend in net sales and profits over the years, with a notable decline from Mar'19 to Mar'20, followed by a gradual recovery. <BR><BR>Breakdown:<BR>Tejnaksh Health's net sales increased from 11.73 Cr in Mar'23 to 12.90 Cr in Mar'25, reflecting a positive growth trend. However, this is a decrease from the peak of 19.76 Cr in Mar'19. The total operating income also followed a similar pattern, rising to 12.90 Cr in Mar'25 from 11.73 Cr in Mar'23. The company's total expenditure, excluding depreciation, has increased from 8.04 Cr in Mar'23 to 8.82 Cr in Mar'25, indicating rising operational costs. Operating profit (PBDIT) improved to 4.48 Cr in Mar'25 from 4.00 Cr in Mar'23, while profit before tax rose to 3.19 Cr in Mar'25 from 2.51 Cr in Mar'23. The profit after tax also saw an increase, reaching 2.23 Cr in Mar'25 compared to 1.79 Cr in Mar'23. On the balance sheet, total liabilities decreased from 31.23 Cr in Mar'23 to 30.31 Cr in Mar'25, while total assets also slightly declined from 31.23 Cr to 30.31 Cr in the same period. The company's cash flow from operating activities showed a significant drop to 0.00 Cr in Mar'25 from 2.00 Cr in Mar'23, indicating challenges in generating cash from operations. Overall, while Tejnaksh Health has shown some recovery in sales and profits, it faces pressures on cash flow and rising costs.

Who are the top shareholders of the Tejnaksh Health.?

The top shareholder of Tejnaksh Health is Ashish Vishwas Rawandale, holding 38.15%. The highest public shareholder is Sheetal Utkarsh Rawandale at 1.45%, with individual investors owning a total of 23.58%.

The top shareholders of Tejnaksh Health include the promoters, with Ashish Vishwas Rawandale holding the largest share at 38.15%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sheetal Utkarsh Rawandale, who owns 1.45%. Additionally, individual investors collectively hold 23.58% of the company.

Is Tejnaksh Health. overvalued or undervalued?

As of July 30, 2024, Tejnaksh Health is considered very attractive and undervalued with a PE ratio of 19.05, strong growth potential indicated by a PEG ratio of 0.54, and favorable comparisons to peers like Max Healthcare and Apollo Hospitals, despite a challenging year with a stock return of -11.6%.

As of 30 July 2024, the valuation grade for Tejnaksh Health has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 19.05, an EV to EBITDA ratio of 10.84, and a PEG ratio of 0.54, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Tejnaksh Health stands out favorably; for instance, Max Healthcare is deemed very expensive with a PE ratio of 100.29, while Apollo Hospitals has a PE ratio of 69.03. The company's solid return on capital employed (ROCE) of 12.73% and return on equity (ROE) of 9.15% further reinforce its attractiveness. Despite a challenging year with a stock return of -11.6% compared to the Sensex's 7.62%, the current valuation metrics suggest that Tejnaksh Health presents a compelling investment opportunity.

What is the technical trend for Tejnaksh Health.?

As of June 6, 2025, Tejnaksh Health's trend has shifted to sideways, with mixed indicators showing mild bullish momentum on the weekly MACD and KST, while daily moving averages and Bollinger Bands suggest a consolidation phase without a clear directional bias.

As of 6 June 2025, the technical trend for Tejnaksh Health has changed from mildly bearish to sideways. The current stance is neutral, with a mix of indicators influencing the outlook. The weekly MACD and KST are both mildly bullish, suggesting some positive momentum, while the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mildly bearish stance on the weekly chart and sideways on the monthly chart. Overall, the lack of strong signals from the RSI and Dow Theory indicates a consolidation phase without a clear directional bias.

What is the bonus history of the Tejnaksh Health.?

Tejnaksh Health's recent bonus history includes a 36:10 bonus issued on April 26, 2018, with a record date of April 28, 2018, and a previous 1:1 bonus issued on March 8, 2017, with a record date of March 9, 2017.

Tejnaksh Health has a notable bonus history. The most recent bonus issue was a 36:10 ratio, which was announced with an ex-date of April 26, 2018, and a record date of April 28, 2018. Prior to that, the company issued a bonus with a 1:1 ratio, which had an ex-date of March 8, 2017, and a record date of March 9, 2017. If you have any more questions about Tejnaksh Health or its financial activities, feel free to ask!

Has Tejnaksh Health. declared dividend?

No Dividend History Available